IGM Biosciences Inc Cash Flow-to-Debt Ratio
IGM Biosciences Inc cash flow-to-debt ratio. IGM Biosciences Inc (IGMS) has a Cash Flow-to-Debt Ratio of -8.38x as of June 2025, meaning its operating cash flow of $-50.79 Million could theoretically repay -8% of its total liabilities ($6.06 Million) in one year. Check IGMS operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of IGM Biosciences Inc (2017–2024)
Cash flow-to-debt ratio of IGM Biosciences Inc from 2017 to 2024. Historical debt coverage capacity for IGM Biosciences Inc across 8 annual periods. Check IGM Biosciences Inc investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
IGM Biosciences Inc Cash Flow-to-Debt Ratio by Year (2017–2024)
IGM Biosciences Inc cash flow-to-debt ratio by year from 2017 to 2024. Year-by-year debt coverage analysis for IGM Biosciences Inc. For the full cash flow conversion analysis, see cash efficiency ratio of IGM Biosciences Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.70x | $-153.00 Million | $217.54 Million | ▲ +19.4% |
| 2023 | -0.87x | $-192.23 Million | $220.18 Million | ▼ -3274.7% |
| 2022 | -0.03x | $-5.85 Million | $226.24 Million | ▲ +98.9% |
| 2021 | -2.34x | $-124.34 Million | $53.22 Million | ▲ +6.9% |
| 2020 | -2.51x | $-67.30 Million | $26.82 Million | ▼ -17.5% |
| 2019 | -2.14x | $-45.12 Million | $21.12 Million | ▼ -644.0% |
| 2018 | -0.29x | $-20.04 Million | $69.81 Million | ▼ -16.1% |
| 2017 | -0.25x | $-10.36 Million | $41.89 Million | — |